Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results
Lespek Kutumbetov, Balzhan Myrzakhmetova, Aiganym Tussipova, Gulzhan Zhapparova, Talshyngul Tlenchiyeva, Karina Bissenbayeva, Kuanysh Zhapar, Kuandyk Zhugunissov, Sergazy Nurabayev, Aslan Kerimbayev · 2024
Read Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results by Lespek Kutumbetov, Balzhan Myrzakhmetova, Aiganym Tussipova, Gulzhan Zhapparova, Talshyngul Tlenchiyeva, Karina Bissenbayeva, Kuanysh Zhapar, Kuandyk Zhugunissov, Sergazy Nurabayev, Aslan Kerimbayev (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11728456.txt.
Description
Lespek Kutumbetov and co-authors tested a live weakened COVID-19 vaccine in animals in 2024. The vaccine, called QazCOVID-Live, was made in Kazakhstan by passing the virus many times through lab cells to weaken it. Tests covered mice, rats, hamsters, and guinea pigs.
Safety checks found no major harm, even at high doses, and no allergy-type reactions of either the fast or slow kind. Shots and nose delivery both raised strong virus-blocking antibodies, with nose routes doing best. Checks on stability and spread supported that the weakened virus stays mild. The team concludes the vaccine is ready to move toward human trials.
Catalog record
| CREATOR | Lespek Kutumbetov, Balzhan Myrzakhmetova, Aiganym Tussipova, Gulzhan Zhapparova, Talshyngul Tlenchiyeva, Karina Bissenbayeva, Kuanysh Zhapar, Kuandyk Zhugunissov, Sergazy Nurabayev, Aslan Kerimbayev |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |